# US 2026/0028398 A1 · Recombinant humanized monoclonal antibody targeting human gprc5d and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028398 A1
- Document ID: US20260028398A1
- Status: Published application
- Kind: A1
- Application number: 18/997,034
- Filed: 2023-08-25
- Published: 2026-01-29
- Earliest claimed: 2022-08-30
- Assignees: Suzhou Dima Biotechnology Co., Ltd
- Applicants: Suzhou Dima Biotechnology Co., Ltd
- Inventors: Donghui MA; Kaikai ZENG; Antao HE; Shujuan HONG; Fen MEI
- Web page: https://patentgrep.com/patent/US20260028398A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/13: Antibody-based
- A61K 2239/29: Multispecific CARs
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/03: containing a transmembrane segment
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A specific recombinant humanized monoclonal antibody targeting human GPRC5D can be used in ELISA and flow detection methods, and can be used for diagnosis and treatment targeting GPRC5D protein. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, and the amino acid sequence and nucleotide sequence of the monoclonal antibody can be used alone or in double-stranded combination. In addition, the sequences of the specific recombinant humanized monoclonal antibody targeting human GPRC5D can be constructed into biological materials or preparations such as monoclonal antibodies, antibody conjugates, bispecific antibodies, CAR-immune cells, etc., and can be used for the diagnosis and treatment of GPRC5D-related diseases.

## Claims

### Claim 1

An antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region, wherein the heavy chain variable region comprises the following CDRs:
VH-CDR1 as shown in SEQ ID NO: 44, 78, 1, 33, 67, 22, or 87;
VH-CDR2 as shown in SEQ ID NO: 59, 45, 79, 12, 34, 68, 2, 23, 54, or 88; and
VH-CDR3 as shown in SEQ ID NO: 60, 46, 69, 13, 35, 69, 3, 24, 55, or 89; wherein the antibody or its antigen-binding fragment specifically binds to GPRC5D, preferably human GPRC5D.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof further comprises a light chain variable region, wherein the light chain variable region comprises the following CDRs:
VL-CDR1 as shown in SEQ ID NO: 61 47, 80, 14, 36, 70, 4, 25, 47, or 90;
VL-CDR2 as shown in SEQ ID NO: 37, 15, 71, 5, or 26; and
VL-CDR3 as shown in SEQ ID NO: 48, 81, 16, 38, 72, 6, 27, 48, or 91.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 62 49, 82, 17, 39, 73, 7, 28, 56, or 92.

### Claim 4 (depends on 2)

The antibody or antigen-binding fragment thereof of claim 2, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 64, 51, 84, 19, 41, 75, 9, 30, or 94.

### Claim 5 (depends on 1)

A recombinant protein, comprising: (i) the antibody or antigen-binding fragment thereof of claim 1; and (ii) an optional tag sequence for assisting in expression and/or purification.

### Claim 6 (depends on 1)

A polynucleotide encoding a polypeptide selected from the group consisting of: (1) the antibody or antigen-binding fragment thereof of claim 1; and (2) the recombinant protein comprising the antibody or antigen-binding fragment thereof and an optional tag sequence for assisting in expression and/or purification.

### Claim 7 (depends on 6)

A vector containing the polynucleotide of claim 6.

### Claim 8 (depends on 1)

An immunoconjugate, comprising: (a) the antibody or antigen-binding fragment thereof of claim 1 or the recombinant protein comprising the antibody or antigen-binding fragment thereof and an optional tag sequence for assisting in expression and/or purification; and (b) a coupled moiety selected from the group consisting of detectable labels, drugs, toxins, cytokines, radioactive isotopes, and enzymes.

### Claim 9 (depends on 1)

A chimeric antigen receptor, wherein the antigen-binding domain of the chimeric antigen receptor comprises the antibody or antigen-binding fragment thereof of claim 1.

### Claim 10 (depends on 1)

An immune cell, wherein the immune cell expresses or displays on its cell membrane the antibody or antigen-binding fragment thereof of claim 1.

### Claim 11 (depends on 1)

A bispecific antibody, comprising the antibody or antigen-binding fragment thereof of claim 1.

### Claim 12 (depends on 11)

The bispecific antibody of claim 11, wherein the bispecific antibody further comprises an antibody or an antigen-binding fragment thereof targeting CD3.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A pharmaceutical composition, comprising an active ingredient selected from the group consisting of: the antibody or antigen-binding fragment thereof of claim 1, or the recombinant protein comprising the antibody or antigen-binding fragment thereof and an optional tag sequence for assisting in expression and/or purification or the bispecific antibody comprising the antibody or antigen-binding fragment thereof, and a combination thereof; and (z2) a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method for treating diseases associated with high expression of GPRC5D, comprising a step of administering to a subject in need thereof the antibody or antigen-binding fragment thereof of claim 1, or the recombinant protein comprising the antibody or antigen-binding fragment thereof and an optional tag sequence for assisting in expression and/or the bispecific antibody comprising the antibody or antigen-binding fragment thereof.

### Claim 16 (depends on 8)

A pharmaceutical composition, comprising the immunoconjugate of claim 8, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 10)

A pharmaceutical composition, comprising the immune cell of claim 10, and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 8)

A method for treating diseases associated with high expression of GPRC5D, comprising a step of administering to a subject in need thereof the immunoconjugate of claim 8.

### Claim 19 (depends on 10)

A method for treating diseases associated with high expression of GPRC5D, comprising a step of administering to a subject in need thereof the immune cell of claim 10.

### Claim 20 (depends on 1)

A non-diagnostic method for detecting GPRC5D protein in a sample in vitro, comprising the following steps:
(s1) in vitro, contacting the sample with the antibody or antigen-binding fragment thereof of claim 1;
(s2) detecting whether an antigen-antibody complex is formed, wherein the formation of the complex indicates the presence of GPRC5D protein in the sample.
